SCHEMBL3857938

SCHEMBL3857938

c1ccc([C](c2ccco2)c2ccco2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.55
ALDH1A1 P00352 5/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
PTPN1 P18031 1/20 0.50
PTGS1 P23219 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
POLB P06746 2/20 0.48
MEN1 O00255 1/20 0.48
THRB P10828 1/20 0.48
APEX1 P27695 1/20 0.48
RECQL P46063 1/20 0.48
PKM P14618 1/20 0.47
RAB9A P51151 4/20 0.47
KCNK3 O14649 1/20 0.46
KCNK9 Q9NPC2 1/20 0.46
GAA P10253 1/20 0.45
NPC1 O15118 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982330 0.84 KMT2A (0.50) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL3862078 0.82 CES2 (0.62) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL1384938 0.81 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL3860533 0.80 KMT2A (0.54) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL3953437 0.77 ALDH1A1 (0.73) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL2459083 0.77 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL28709131 0.77 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL23340458 0.76 CES2 (0.62) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL15665397 0.76 CES2 (0.75) SMN1; SMN2ALDH1A1MAPTKMT2ACES2
SCHEMBL3853904 0.76 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1MAPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585970-B2 Method of polynucleotide synthesis using modified support AGILENT TECHNOLOGIES, INC. (US) 2009-09-08 US disclosed
US-7427679-B2 Precursors for two-step polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-09-23 US disclosed
US-7417139-B2 Method for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-08-26 US disclosed
US-7385050-B2 Cleavable linker for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-06-10 US disclosed
US-7193077-B2 Exocyclic amine triaryl methyl protecting groups in two-step polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2007-03-20 US disclosed
US-20050186580-A1 Quality control method for array manufacture AGILENT TECHNOLOGIES, INC. 2005-08-25 US disclosed
US-20050186579-A1 MALDI-MS analysis of nucleic acids bound to a surface AGILENT TECHNOLOGIES, INC. 2005-08-25 US disclosed
EP-1512691-A1 Protecting groups for two-step polynucleotide synthesis Agilent Technologies Inc (US) 2005-03-09 EP disclosed
US-20050048496-A1 Method of polynucleotide synthesis using modified support AGILENT TECHNOLOGIES, INC. 2005-03-03 US disclosed
US-20050048601-A1 Method for polynucleotide synthesis REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-03 US disclosed
US-20050049411-A1 Exocyclic amine triaryl methyl protecting groups in two step polynucleotide synthesis REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-03 US disclosed
US-20050048497-A1 Cleavable linker for polynucleotide synthesis THE REGENTS OF THE UNIVERSITY OF COLORADO 2005-03-03 US disclosed
US-20050049407-A1 Precursors for two-step polynucleotide synthesis THE REGENTS OF THE UNIVERSITY OF COLORADO 2005-03-03 US disclosed
EP-1510523-A1 Precurors for two-step polynucleotide synthesis Agilent Technologies Inc (US) 2005-03-02 EP disclosed
EP-1510522-A1 Method of polynucleotide synthesis using modified support Agilent Technologies Inc (US) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050048496-A1 Method of polynucleotide synthesis using modified support POLN, POLRMT, POLM SMN1; SMN2 388/4885ALDH1A1 4090/4885MAPT 3620/4885
US-20050048601-A1 Method for polynucleotide synthesis POLN, RNGTT, NSUN2 SMN1; SMN2 652/4885ALDH1A1 4398/4885MAPT 4158/4885
US-20050049407-A1 Precursors for two-step polynucleotide synthesis NT5C3B, NSUN2, POLN SMN1; SMN2 416/4885ALDH1A1 4145/4885MAPT 4124/4885
US-20050048497-A1 Cleavable linker for polynucleotide synthesis TYMP, POLN, CPSF1 SMN1; SMN2 296/4885ALDH1A1 4036/4885MAPT 4176/4885
US-20050049411-A1 Exocyclic amine triaryl methyl protecting groups in two step polynucleotide synthesis NT5C3B, RNMT, NSUN2 SMN1; SMN2 305/4885ALDH1A1 4399/4885MAPT 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.